Who Exports Empagliflozin from India — 170 Suppliers Behind a $6.7M Market
India's empagliflozin export market is supplied by 170 active exporters who collectively shipped $6.7M across 3,528 shipments. LAWRENCE WALTER leads with a 12.7% market share, followed by BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED and HEXA HEALTH CARE PRIVATE LIMITED. The top 5 suppliers together control 45.3% of total export value, reflecting a moderately competitive market structure.
Top Empagliflozin Exporters from India — Ranked by Export Value
LAWRENCE WALTER is the leading empagliflozin exporter from India, holding a 12.7% share of the $6.7M market across 3,528 shipments from 170 exporters. The top 5 suppliers — LAWRENCE WALTER, BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED, HEXA HEALTH CARE PRIVATE LIMITED, SAVA HEALTHCARE LIMITED, SCOTT EDIL PHARMACIA LIMITED — collectively control 45.3% of total export value, indicating a competitive market. Individual shares are: LAWRENCE WALTER (12.7%), BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED (10.2%), HEXA HEALTH CARE PRIVATE LIMITED (10.1%), SAVA HEALTHCARE LIMITED (8.5%), SCOTT EDIL PHARMACIA LIMITED (3.9%).
Top Empagliflozin Exporters from India
Ranked by export value · 170 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | LAWRENCE WALTER JARDIANCE 25MG SIZE-90 TABS/PACKSEMPAGLIFLOZIN 25 MGEMPAGLIFLOZIN 10MG | $848.8K | 3 | 12.7% |
| 2 | BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED JARDIANCE 90/10 MGJARDIANCE 90/25 MGJARDIANCE 90/10MG | $681.8K | 2 | 10.2% |
| 3 | HEXA HEALTH CARE PRIVATE LIMITED JARDIANCE 25 MG 90 TAB EMPAGLIFLOZINJARDIANCE 10 MG 90 TAB EMPAGLIFLOZINJARDIANCE 25MG 90 TAB EMPAGLIFLOZIN | $675.4K | 1 | 10.1% |
| 4 | SAVA HEALTHCARE LIMITED JARDIANCE 25 MG 90 TAB EMPAGLIFLOZINJARDIANCE 10 MG 90 TAB EMPAGLIFLOZINJARDIANCE 25MG 90 TAB EMPAGLIFLOZIN | $569.5K | 1 | 8.5% |
| 5 | SCOTT EDIL PHARMACIA LIMITED HARMLESS MEDICINES FOR HUMAN CONSUMPTION-EMPAGLIFLOZIN TAB 25MG (EMPARUX-M (EMPAGLIFLOZIN AND METFORMIN H | $260.7K | 4 | 3.9% |
| 6 | PLEASANT EXPORTS JARDIANCE 25 MG 90 TAB EMPAGLIFLOZINJARDIANCE 10 MG 90 TAB EMPAGLIFLOZINJARDIANCE 25MG 90 TAB EMPAGLIFLOZIN | $254.7K | 2 | 3.8% |
| 7 | DELTA BIOPHARMA PRIVATE LIMITED "EMFLOZIN 25MG MYR REGN NO: 2610EA00358"EMFLOZIN 10MG PACK SIZE: 3X10'S MYR REGN NO: 2610EA00359"EMFLOZIN 25[EMPAGLIFLOZIN TABLETS 25 MG | $234.4K | 2 | 3.5% |
| 8 | LOTUS INTERNATIONAL EMPAGLIFLOZIN 25 MGEMPAGLIFLOZIN 10MGEMPAGLIFLOZIN 25MG | $227.9K | 2 | 3.4% |
| 9 | KWALITY PHARMACEUTICALS LIMITED HARMLESS MEDICINES FOR HUMAN CONSUMPTION-EMPAGLIFLOZIN TAB 25MG (EMPAGLIFLOZIN TABLET | $205.3K | 5 | 3.1% |
| 10 | ALPHA-PHARMA HEALTHCARE PRIVATE LIMITED EMPAGLIFLOZIN 25 MGEMPAGLIFLOZIN 10MGEMPAGLIFLOZIN 25MG | $157.3K | 5 | 2.3% |
| 11 | GAIA TRADE PRIVATE LIMITED JARDIANCE 25MG SIZE-90 TABS/PACKSEMPAGLIFLOZIN 25 MGEMPAGLIFLOZIN TABLET | $151.4K | 3 | 2.3% |
| 12 | GANPATI EXIM INC EMPAGLIFLOZIN 25 MGEMPAGLIFLOZIN 10MGEMPAGLIFLOZIN 25MG | $135.6K | 1 | 2.0% |
| 13 | GLOBAL PHARMA HEALTHCARE PRIVATE LIMITED EMPAGLIFLOZIN TABLET | $134.5K | 3 | 2.0% |
| 14 | SHREE SSD PHARMA PRIVATE LIMITED EMPAGLIFLOZIN 25 MGEMPAGLIFLOZIN 10MGEMPAGLIFLOZIN 25MG | $127.7K | 2 | 1.9% |
| 15 | HEXAMED LIFE SCIENCES LLP HARMLESS MEDICINES FOR HUMAN CONSUMPTION-EMPAGLIFLOZIN TAB 25MG (EMPAGLIFLOZIN 12.5MG & METFORMIN HYDROCH | $121.8K | 1 | 1.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Empagliflozin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Boehringer Ingelheim India Private Limited | Warning Letter, April 202 | Yes, as of March 202 | Yes | Not verified | Received FTC warning letter for improper patent listings. |
| Global Pharma Healthcare Private Limited | Warning Letter, October 2 | No | No | Not verified | FDA cited CGMP violations; firm placed on Import Alert 66-40. |
| Hikal Limited | Warning Letter, August 20 | Yes, as of March 202 | Yes | Not verified | FDA cited contamination issues; firm received warning letter. |
| Glenmark Pharmaceuticals Limited | Warning Letter, July 2025 | Yes, as of March 202 | Yes | Not verified | FDA cited CGMP violations; firm received warning letter. |
| Kenil Healthcare Private Limited | Warning Letter, June 2025 | Yes, as of March 202 | Yes | Not verified | FDA cited CGMP violations; firm received warning letter. |
| Cdymax India Pharma Private Limited | Warning Letter, November | Yes, as of March 202 | Yes | Not verified | FDA cited CGMP violations; firm received warning letter. |
| Hetero Labs Limited | Warning Letter, October 2 | Yes, as of March 202 | Yes | Not verified | FDA cited warehouse missteps; firm received warning letter. |
| Amneal Pharmaceuticals, LLC | Warning Letter, August 20 | Yes, as of March 202 | Yes | Not verified | FDA cited CGMP violations; firm received warning letter. |
| Bhargava Phytolab Private Limited | Warning Letter, December | Yes, as of March 202 | Yes | Not verified | FDA cited CGMP violations; firm received warning letter. |
TransData Nexus reviewed the regulatory standing of 9 leading Empagliflozin exporters from India. 0 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. 9 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Empagliflozin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of Active Pharmaceutical Ingredients (APIs). The city hosts Genome Valley, India's first biotech cluster, and is home to over 800 pharmaceutical companies, including industry leaders such as Dr. Reddy’s Laboratories, Aurobindo Pharma, and Divi’s Laboratories. This concentration of expertise and infrastructure makes Hyderabad a significant player in the manufacturing of APIs like Empagliflozin.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat contributes nearly 28% of India's pharmaceutical production and houses major companies such as Zydus Cadila, Intas Pharmaceuticals, and Torrent Pharmaceuticals. Vadodara, in particular, is home to Century Pharma Ltd., a recognized manufacturer of Empagliflozin API, emphasizing the region's capability in both API and finished dosage form production.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being the financial capital, provides robust infrastructure and connectivity, facilitating the export of pharmaceuticals to global markets. Companies like Cipla, headquartered in Mumbai, leverage this strategic location to distribute products worldwide, including medications like Empagliflozin.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub, housing over 1,000 manufacturing units. The region's growth has been significantly influenced by favorable government policies, including tax incentives, which have attracted numerous pharmaceutical companies. This makes Baddi a key area for the production of various pharmaceuticals, potentially including Empagliflozin.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with multiple suppliers across different clusters to mitigate risks associated with regional disruptions.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of suppliers, especially those in Hyderabad and Vadodara, known for their API production.
- Leverage Export Infrastructure: Utilize the export facilities in the Mumbai-Thane-Raigad region to streamline logistics and distribution.
- Consider Cost Advantages: Explore partnerships with manufacturers in Baddi to benefit from tax incentives and cost-effective production.
By strategically sourcing from these diverse pharmaceutical clusters, companies can ensure a robust and reliable supply chain for Empagliflozin.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Empagliflozin exporters from India
Alkem Laboratories Ltd — Alkem launches generic Empagliflozin under brand name 'Empanorm'
Alkem Laboratories introduced 'Empanorm,' a generic version of Empagliflozin, priced approximately 80% lower than the innovator product. The launch includes various combinations such as Empagliflozin with Linagliptin, Sitagliptin, and Metformin. - IMPACT: The introduction of cost-effective generics is likely to intensify competition in the Empagliflozin export market.
Impact: The introduction of cost-effective generics is likely to intensify competition in the Empagliflozin export market.
Glenmark Pharmaceuticals — Glenmark launches generic Empagliflozin in India
Glenmark Pharmaceuticals launched 'Glempa,' a generic version of Empagliflozin, along with fixed-dose combinations like Glempa-L and Glempa-M, targeting improved glycemic control in adults with type 2 diabetes mellitus. - IMPACT: The availability of new generics may affect the market share of existing exporters.
Impact: The availability of new generics may affect the market share of existing exporters.
National Pharmaceutical Pricing Authority (NPPA) — NPPA sets ceiling prices for Empagliflozin-based formulations
The NPPA fixed ceiling prices for 84 drug formulations, including Empagliflozin-based combinations, to enhance affordability and accessibility of diabetes treatments. - IMPACT: Price controls may influence export pricing strategies for Empagliflozin products.
Impact: Price controls may influence export pricing strategies for Empagliflozin products.
Common Questions — Empagliflozin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which empagliflozin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, LAWRENCE WALTER leads with 947 recorded shipments worth $848.8K. BOEHRINGER INGELHEIM INDIA PRIVATE LIMITED (28 shipments) and HEXA HEALTH CARE PRIVATE LIMITED (113 shipments) are also established high-volume exporters.
Q How many empagliflozin manufacturers are there in India?
India has 170 active empagliflozin exporters with a combined export market of $6.7M across 3,528 shipments to 75 countries. The top 5 suppliers hold 45.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for empagliflozin from India?
Average FOB unit price: $35.46 per unit, ranging from $0.01 to $5169.98. Average shipment value: $1.9K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 170 verified Indian exporters of Empagliflozin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,528 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 75 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,528 Verified Shipments
170 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists